pentobarbital will minimize the extent or outcome of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Use of other solutions is strongly advised when linagliptin is always to be administered by using a CYP3A4 inducer buprenorphine subdermal implant